Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic

被引:31
作者
Hawryluk, Elena B. [2 ]
Sober, Arthur J. [2 ]
Piris, Adriano [1 ]
Nazarian, Rosalynn M. [1 ]
Hoang, Mai P. [1 ]
Tsao, Hensin [2 ]
Mihm, Martin C., Jr. [3 ]
Duncan, Lyn M. [1 ]
机构
[1] Massachusetts Gen Hosp, Dermatopathol Unit, Pathol Serv, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Dept Dermatol, Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
consensus; dermatopathology; melanocytic tumors; melanoma; pigmented lesions; PRIMARY CUTANEOUS MELANOMA; AMERICAN JOINT COMMITTEE; MALIGNANT-MELANOMA; MITOTIC RATE; HISTOPATHOLOGIC DIAGNOSIS; OBSERVER VARIATION; DYSPLASTIC NEVI; INTEROBSERVER VARIABILITY; PROGNOSTIC-SIGNIFICANCE; PATHOLOGISTS;
D O I
10.1016/j.jaad.2012.02.036
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The histopathologic diagnosis of some melanocytic tumors is extraordinarily difficult. With this in mind, melanocytic tumors from patients referred to the Massachusetts General Hospital (MGH) Pigmented Lesion Clinic (PLC) are routinely reviewed in the MGH Dermatopathology Unit. Objective: We sought to determine the frequency of diagnostically challenging cases from patients treated at the MGH PLC, as measured by a change in the diagnosis upon review of the referral materials. Methods: We retrospectively reviewed the MGH and referral pathology reports for 478 consecutive cutaneous melanocytic tumors: 126 from 1996-1997 and 352 from 2010-2011. Differences in diagnosis and in therapeutic impact were evaluated. Results: Changes in diagnosis occurred in 168 of 478 cases (35%), more frequently when the original diagnostician was a general pathologist (P = .003). A similar fraction of diagnoses were changed from malignant to benign or vice versa, in both historic and contemporary cohorts. In 64 patients (13%), changes in diagnosis led to a change in therapy. Changes in stage or grading led to the most changes in therapy (78%; 50/64) versus changes from benign to malignant or vice versa (22%; 14/64). Limitations: This is a retrospective study with the bias of a tertiary-care referral center. Conclusions: These findings demonstrate the diagnostic difficulty of a subset of melanocytic tumors and highlight the utility of review by more than one pathologist; patient treatment is affected in more than 10% of cases. Identification of melanoma prognostic factors and melanocytic nevus grading led to clinically significant changes in diagnosis leading to a change in patient management. (J Am Acad Dermatol 2012;67:727-35.)
引用
收藏
页码:727 / 735
页数:9
相关论文
共 36 条
  • [1] Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma - An analysis of 3661 patients from a single center
    Azzola, MF
    Shaw, HM
    Thompson, JF
    Soong, SJ
    Scolyer, RA
    Watson, GF
    Colman, MH
    Zhang, YT
    [J]. CANCER, 2003, 97 (06) : 1488 - 1498
  • [2] Final Version of 2009 AJCC Melanoma Staging and Classification
    Balch, Charles M.
    Gershenwald, Jeffrey E.
    Soong, Seng-jaw
    Thompson, John F.
    Atkins, Michael B.
    Byrd, David R.
    Buzaid, Antonio C.
    Cochran, Alistair J.
    Coit, Daniel G.
    Ding, Shouluan
    Eggermont, Alexander M.
    Flaherty, Keith T.
    Gimotty, Phyllis A.
    Kirkwood, John M.
    McMasters, Kelly M.
    Mihm, Martin C., Jr.
    Morton, Donald L.
    Ross, Merrick I.
    Sober, Arthur J.
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6199 - 6206
  • [3] The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma
    Barnhill, RL
    Katzen, J
    Spatz, A
    Fine, J
    Berwick, M
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2005, 32 (04) : 268 - 273
  • [4] Guidelines of care for the management of primary cutaneous melanoma
    Bichakjian, Christopher K.
    Halpern, Allan C.
    Johnson, Timothy M.
    Hood, Antoinette Foote
    Grichnik, James M.
    Swetter, Susan M.
    Tsao, Hensin
    Barbosa, Victoria Holloway
    Chuang, Tsu-Yi
    Duvic, Madeleine
    Ho, Vincent C.
    Sober, Arthur J.
    Beutner, Karl R.
    Bhushan, Reva
    Begolka, Wendy Smith
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 65 (05) : 1032 - 1047
  • [5] Boiko P E, 1994, J Am Board Fam Pract, V7, P371
  • [7] Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
    Buzaid, AC
    Ross, MI
    Balch, CM
    Soong, SJ
    McCarthy, WH
    Tinoco, L
    Mansfield, P
    Lee, JE
    Bedikian, A
    Eton, O
    Plager, C
    Papadopoulos, N
    Legha, SS
    Benjamin, RS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1039 - 1051
  • [8] CLARK WH, 1969, CANCER RES, V29, P705
  • [9] A STUDY OF TUMOR PROGRESSION - THE PRECURSOR LESIONS OF SUPERFICIAL SPREADING AND NODULAR MELANOMA
    CLARK, WH
    ELDER, DE
    GUERRY, D
    EPSTEIN, MN
    GREENE, MH
    VANHORN, M
    [J]. HUMAN PATHOLOGY, 1984, 15 (12) : 1147 - 1165
  • [10] HISTOPATHOLOGIC DIAGNOSIS OF DYSPLASTIC NEVI - CONCORDANCE AMONG PATHOLOGISTS CONVENED BY THE WORLD-HEALTH-ORGANIZATION-MELANOMA-PROGRAM
    CLEMENTE, C
    COCHRAN, AJ
    ELDER, DE
    LEVENE, A
    MACKIE, RM
    MIHM, MC
    RILKE, F
    CASCINELLI, N
    FITZPATRICK, TB
    SOBER, AJ
    [J]. HUMAN PATHOLOGY, 1991, 22 (04) : 313 - 319